Last reviewed · How we verify
Pragabalin
Pragabalin, developed by Baskent University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not available. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Pragabalin |
|---|---|
| Also known as | pregabalin 150 mg, Lyrica, Pfezir, Almanya |
| Sponsor | Baskent University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pragabalin CI brief — competitive landscape report
- Pragabalin updates RSS · CI watch RSS
- Baskent University portfolio CI